Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Amag Slumps on Ferahame Recall in Switzerland

By Pharmaceutical Processing | May 23, 2013

NEW YORK (AP) — Shares of Amag Pharmaceuticals Inc. sank Wednesday after the company said it is taking a batch of its anemia drug Feraheme off the market following the death of a patient.

THE SPARK: Amag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland. Amag said four patients experienced severe allergic reactions to the drug, and one of those patients died. That batch was sold only in Switzerland, and the recall doesn’t affect any other countries.

THE BIG PICTURE: The FDA approved Feraheme, or ferumoxytol, in 2009, as a treatment for iron deficiency anemia. In the U.S., it is approved for use in patients with chronic kidney disease. European Union regulators approved the drug in 2012 under the name Rienso. Takeda markets the drug in Europe.

Amag reported $58 million in U.S. sales of Feraheme in 2012, and it expects $63 million to $67 million in 2013.

Severe allergic reactions are a side effect common to several anemia drugs. Early this year Affymax Inc. and Takeda pulled their anemia drug Omontys off the market after several people taking it died and about 50 had severe allergic reactions. It’s not clear if Omontys will make it back to the market. The Food and Drug Administration approved Omontys in March 2012, several years after Feraheme was approved.

Sales of Amgen Inc.’s drugs Aranesp and Epogen have fallen over the years because of a variety of safety concerns and limits on their use.

THE ANALYSIS: Leerink Swann analyst Joseph Schwartz said he does not think the recall will have a big impact on Feraheme sales in larger markets. He said Feraheme appears to have a lower rate of side effects than competing drugs even though patients with chronic kidney disease tend to have a lot of health problems.

He maintained an “Outperform” rating on the stock.

SHARE ACTION: Amag shares fell $2.68, or 10.7 percent, to $22.40 in afternoon trading. The stock has climbed 49 percent since March 1 and has nearly doubled in value over the last year, reaching a two-year high of $25.67 on May 15.

 

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE